Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ranolazine CV Therapeutics.

Mario Marzilli1

  • 1University of Siena, Postgraduate School of Cardiology, Policlinico Le Scotte, Viale Bracci 74, 53100 Siena, Italy. marzilli@unisi.it

Current Opinion in Investigational Drugs (London, England : 2000)
|April 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.

European heart journal·2026
Same author

Early combination therapy with trimetazidine rapidly improves symptoms and quality of life in patients recently diagnosed with stable angina: The COMBINE angina study.

International journal of cardiology·2025
Same author

Myocardial Ischaemic Syndromes: Shifting from a Coronary-centric to a Substrate-based Nomenclature is More Accurate and Inclusive.

European cardiology·2025
Same author

Corrigendum to "HIV-Related Atherosclerosis: State-of-the-Art-Review" [Current Problems in Cardiology, Volume 48, Issue 9, September 2023, 101783].

Current problems in cardiology·2024
Same author

Myocardial Ischemic Syndromes: A New Nomenclature to Harmonize Evolving International Clinical Practice Guidelines.

Circulation·2024
Same author

Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines.

European heart journal·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

CV Therapeutics is developing ranolazine (Ranexa) to treat angina and acute coronary syndromes. The Phase III MERLIN TIMI-36 study was ongoing in October 2004, with completion expected in early 2005.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Medicine

Background:

  • Ranolazine (Ranexa) is a metabolic modulator developed by CV Therapeutics.
  • It functions as a partial fatty acid oxidation inhibitor.
  • The drug is investigated for treating angina and acute coronary syndromes.

Purpose of the Study:

  • To evaluate the efficacy and safety of ranolazine in patients with angina and acute coronary syndromes.
  • To assess ranolazine's role as a metabolic modulator in cardiovascular disease.

Main Methods:

  • The study involves Phase III clinical trials.
  • Enrollment in the MERLIN TIMI-36 study was ongoing as of October 2004.
  • The study was anticipated to be completed by the end of Q1 2005.

Related Experiment Videos

Main Results:

  • Data on the efficacy and safety of ranolazine are being collected.
  • The study aims to determine the clinical benefit of partial fatty acid oxidation inhibition.

Conclusions:

  • The ongoing MERLIN TIMI-36 study will provide key insights into ranolazine's therapeutic potential.
  • Results are expected to inform treatment strategies for angina and acute coronary syndromes.